Precigen Receives Orphan Drug Designation For PRGN-2012 For Treatment Of Recurrent Respiratory Papillomatosis From The European Commission
Portfolio Pulse from Benzinga Newsdesk
Precigen has been granted Orphan Drug Designation by the European Commission for PRGN-2012, a treatment for Recurrent Respiratory Papillomatosis (RRP). This designation is expected to provide Precigen with certain benefits, including market exclusivity upon regulatory approval, assistance with clinical development, and reduced regulatory fees.
January 16, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precigen's receipt of Orphan Drug Designation for PRGN-2012 by the European Commission is a positive development, likely to enhance the company's prospects in the European market for RRP treatment.
The Orphan Drug Designation is a significant milestone for Precigen, as it not only recognizes the potential of PRGN-2012 as a treatment for RRP but also provides a range of benefits that can accelerate its development and commercialization. These benefits include market exclusivity, which protects against competition for a period post-approval, as well as support and reduced costs during the regulatory process. This news is likely to be viewed positively by investors and could lead to an increase in Precigen's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90